Cellular Biomedicine Group, Inc.: Cellular Biomedicine (NASDAQ: CBMG), clinical-stage biopharma, will bring the first marketed CAR-T cell therapy, Kymriah, to China (the second largest healthcare market) with its strategic collaboration with Novartis. Validates CBMG's in-house cell manufacturing capabilities developed in partnership with General Electric and Thermo Fisher. CBMG's proprietary immuno-oncology pipeline includes BCMA, CD22, TCR-T for HCC and TIL for the treatment of NSCLC and other solid tumors.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Asia
Disease Space
Immuno-Oncology, Oncology
Finance
Revenues
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
1345 Avenue of the Americas
11th Floor
New York, NY 10105
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.